Literature DB >> 92490

An in vitro procedure for the estimation of thyroid hormone releasing factors in sera of thyrotoxic patients.

M L Maayan, E M Volpert, F P Dawry.   

Abstract

LATS containing sera and a number of Graves' disease sera stimulated T4 release from mouse thyroids in vitro as determined by RIA, thus confirming the presence of a thyroid hormone releasing factor in sera of thyrotoxic patients. The pattern of stimulation was similar to that previously shown for TSH in terms of T4 release time sequence. cAMP increase and catecholamine inhibition via alpha-adrenergic receptors. In the same in vitro system, neutralization with a human thyroid homogenate showed presence of LATS-Protector (LPA) in LATS negative thyrotoxic sera. The present study describes a simpler procedure for estimating LATS or similar activity, as compared to the McKenzie assay, and suggests identical receptor sites for TSH and other thyroid stimulators.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 92490     DOI: 10.1007/BF03350973

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  11 in total

1.  Thyroid secretion in vitro: multiple actions of agents affecting secretion.

Authors:  J A Williams; J Wolff
Journal:  Endocrinology       Date:  1971-01       Impact factor: 4.736

2.  Occurrence in thyrotoxicosis of a gamma globulin which protects LATS from neutralization by an extract of thyroid gland.

Authors:  D D Adams; T H Kennedy
Journal:  J Clin Endocrinol Metab       Date:  1967-02       Impact factor: 5.958

3.  A new in vitro assay for thyroid-stimulating hormone.

Authors:  J Brown; D S Munro
Journal:  J Endocrinol       Date:  1967-08       Impact factor: 4.286

4.  Induction of a LATS-like response by thyroglobulin in the McKenzie assay system.

Authors:  L C Wood; A Burger; M Peterson; S H Ingbar
Journal:  Endocrinology       Date:  1973-05       Impact factor: 4.736

5.  Inhibition of the response of mouse thyroid to tryrotropin induced by chronic triiodothyronine treatment.

Authors:  M Gafni; N Sirkis; J Gross
Journal:  Endocrinology       Date:  1975-11       Impact factor: 4.736

6.  Charge effects in the activation of adenylate cyclase.

Authors:  J Wolff; G H Cook
Journal:  J Biol Chem       Date:  1975-09-10       Impact factor: 5.157

7.  Identification of subgroups of euthyroid graves's ophthalmopathy.

Authors:  D H Solomon; I J Chopra; U Chopra; F J Smith
Journal:  N Engl J Med       Date:  1977-01-27       Impact factor: 91.245

8.  Thyroid stimulators in health and disease.

Authors:  R Hall; B R Smith; E D Mukhtar
Journal:  Clin Endocrinol (Oxf)       Date:  1975-03       Impact factor: 3.478

9.  Inhibition of thyrotropin- and dibutyryl cyclic AMP-induced secretion of thyroxine and triiodothyronine by catecholamines.

Authors:  M L Maayan; A F Debons; I Krimsky; E M Volpert; A From; F Dawry; E Siclari
Journal:  Endocrinology       Date:  1977-07       Impact factor: 4.736

10.  Thyroid antigen stimulates lymphocytes from patients with Graves' disease to produce thyroid-stimulating immunoglobulin (TSI).

Authors:  A J Knox; C von Westarp; V V Row; R Volpé
Journal:  J Clin Endocrinol Metab       Date:  1976-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.